Galera reports Q2 net loss $14.6M ($0.54/sh); NDA for avasopasem on track by end of 2022

Galera Therapeutics, Inc.

2022-Q2 EPS reported -$1.12

Net loss $14.6M ($0.54 per share) in Q2 2022, compared to $22.4M ($0.88/sh) in Q2 2021.
R&D expenses $6.7M (down from $16.0M YoY); cash and investments $52.0M as of June 30, 2022.
Phase 3 ROMAN data: avasopasem reduced SOM incidence and days; NDA submission on track for end of 2022.
Phase 1 GRECO-1: rucosopasem+SBRT showed 6/7 patients with partial response or stable disease; Phase 2 enrollment completion expected 2H 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.